A Phase I Study of FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response
Latest Information Update: 25 Sep 2023
At a glance
- Drugs FMPV-1 (Primary) ; Granulocyte macrophage colony stimulating factor (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Hubro Therapeutics
- 20 Sep 2023 Status changed from active, no longer recruiting to completed.
- 08 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2022 New trial record